Amgen ($AMGN) is paying up to resolve claims that it broke the rules while marketing anemia drug Aranesp and anti-inflammatory blockbuster Enbrel. The company has settled with 48 states for $71 million, marking the latest state-level crackdown on alleged marketing violations in the pharma industry. Amgen has promised not to make misleading or deceptive claims in promoting the two meds and to stop lobbying for treatment guidelines that sanction off-label use, too. More